Show notes
Episode four takes the incidental cyst through the same endoscopic-ultrasound-and-fluid pathway used for the autoimmune mass, but the cost runs the other way: resecting a cyst that was never going to become cancer commits a patient to major-operation morbidity for nothing. The organizing question is whether the epithelium is mucinous, because only the mucinous lesions carry progressive dysplasia, and the fluid answers it, CEA and glucose for mucin, amylase for duct communication. Demographics and imaging give a pretest guess, then the biochemistry classifies the lesion cleanly. The intraductal mucinous neoplasm is the one left to surveil, where high-risk stigmata mandate resection, worrisome features trigger endoscopic ultrasound, and a size-stratified MRI schedule runs only while it can still change management. Thresholds are the trap throughout.
Topics covered
Mucinous versus non-mucinous as the organizing principle
Demographics and imaging of the five entities
Mucinous cystic neoplasm versus serous cystadenoma
Fluid biochemistry: CEA, glucose, amylase
The four-quadrant classification by CEA and amylase
Clinical pivots by cyst type
High-risk stigmata versus worrisome features
The five- and ten-millimeter thresholds
Size-stratified surveillance and stopping rules
Key decisions
The decision to watch or resect tracks whether the epithelium is mucinous, since intraductal and mucinous cystic neoplasms harbor progressive dysplasia while serous cystadenoma, pseudocyst, and retention cysts have negligible malignant potential.
A cyst fluid CEA above one hundred ninety-two nanograms per milliliter favors mucinous origin, a glucose below fifty is highly sensitive for a mucinous cyst, and an amylase above two hundred fifty units per liter supports duct communication.
A mucinous cystic neoplasm goes to resection in a fit candidate regardless of size, while a confidently diagnosed serous cystadenoma needs no surveillance at all.
Any one of the four high-risk stigmata, obstructive jaundice with a cystic head lesion, an enhancing mural nodule five millimeters or larger, a main pancreatic duct ten millimeters or larger, or suspicious cytology, mandates surgical referral with no confirmatory aspiration needed.
Worrisome features such as a cyst three centimeters or larger, an enhancing nodule under five millimeters, a main duct between five and ten millimeters, or growth of two and a half millimeters or more per year trigger endoscopic ultrasound rather than the operating room.
A new five-millimeter enhancing nodule crosses from worrisome into high-risk regardless of prior stability, so a four-millimeter nodule keeps a patient in surveillance while a five-millimeter nodule is the threshold for resection.
Surveillance continues only while it can change management, stopping when the patient is no longer a surgical candidate or life expectancy is under ten years, with exceptions for younger, familial, or genetically at-risk patients.
For the full chapter with MCQs, tables, and primary-guideline references, visit www.boardpearls.com.
Questions or feedback: [email protected].